-transparent.png){kind=logo}
The tumor marker study attempts to make a diagnosis before the clinical diagnosis. We have studied some of these tumor markers (PSA, PAP and acid phosphatase) in 97 patients who suffered from benign prostatic hypertrophy, prostatic cancer and other non-prostatic pathologies. PSA appears to be the best marker, as reported in the literature. The sensitivity and specificity for two different cut off levels (5 and 10 ng/ml) were analyzed in order to determine the best. The statistical analysis was done by the chi-square method. The differences between the tumor markers were not significant for sensitivity. PSA appears to be more sensitive than PAP. Although there are no significant differences for sensitivity between both cut-off levels, and between PSA and PAP. We consider that the 10 ng/ml cut off is better assuming we will have a higher percentage of specificity (p < 0.05).
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
July 1986,
Rinsho byori. The Japanese journal of clinical pathology,
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
January 1989,
Archivos espanoles de urologia,
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
April 1990,
Hinyokika kiyo. Acta urologica Japonica,
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
May 1984,
The Urologic clinics of North America,
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
January 1991,
Meditsinskaia radiologiia,
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
November 1993,
Harefuah,
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
July 1986,
Rinsho byori. The Japanese journal of clinical pathology,
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
January 1991,
Hinyokika kiyo. Acta urologica Japonica,
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
January 1999,
Tumori,
E Casas Terrón, and
M Mari Ruiz, and
E Molina Andreu
January 1983,
Terapevticheskii arkhiv,
